Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $17.0B | $14.9B | $14.3B | $10.3B | $15.0B | $15.7B | $14.2B | $18.2B | $18.0B | $16.4B | $13.5B | $13.0B | $13.7B | $14.1B | $15.0B | $15.1B | $10.6B | $24.8B | $40.0B | $3,359.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Pfizer Inc.'s last 12-month Operating Income is $10.1B, based on the financial report for Sep 29, 2024 (Q3 2024).
Over the last year, Pfizer Inc.'s Operating Income growth was (12.9%). The average annual Operating Income growth rates for Pfizer Inc. have been 2.9% over the past three years, (7.3%) over the past five years.
Over the last year, Pfizer Inc.'s Operating Income growth was (12.9%), which is lower than industry growth of 0.0%. It indicates that Pfizer Inc.'s Operating Income growth is Bad.